SAFETY DATA SHEET
Cat# B2132-50, 250 Lisinopril dehydrate
SDS DATE: Jun 4, 2018

SECTION 1: PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME: Lisinopril dehydrate

PRODUCT CODES: Cat# B2132-50, 250

MANUFACTURER: BioVision, Inc.

ADDRESS: 155 S. Milpitas Boulevard, Milpitas, CA 95035

EMERGENCY PHONE: 858-373-8066

CHEMTREC PHONE: OTHER CALLS: 408-493-1800

FAX PHONE: 408-493-1801

SECTION 2: HAZARDS IDENTIFICATION

<table>
<thead>
<tr>
<th>Component</th>
<th>Description</th>
<th>Volume</th>
<th>Safety Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lisinopril dehydrate</td>
<td>Solid</td>
<td>B2132-50: 50 mg</td>
<td>See below</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B2132-250: 250 mg</td>
<td></td>
</tr>
</tbody>
</table>

**Lisinopril dehydrate:**

Emergency Overview

GHS Classification:

- Reproductive toxicity (Category 1A), H360
- Specific target organ toxicity - repeated exposure (Category 2), Kidney, H373

GHS Label elements, including precautionary statements

Pictogram:

Signal word: Danger

Hazard statement(s):

- H360 May damage fertility or the unborn child.
- H373 May cause damage to organs (Kidney) through prolonged or repeated exposure.

Precautionary statement(s):

- P201 Obtain special instructions before use.
- P202 Do not handle until all safety precautions have been read and understood.
- P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.
- P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
- P308 + P313 IF exposed or concerned: Get medical advice/ attention.
- P405 Store locked up.
- P501 Dispose of contents/ container to an approved waste disposal plant.

HMIS Classification

- Health hazard: 3
- Chronic health hazard: *
- Flammability: 0
- Physical hazards: 0

NFPA Rating

- Health Hazard: 3
- Fire: 0
- Reactivity Hazard: 0

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Product Name/Chemical Name</th>
<th>CAS Number</th>
<th>EC-No.</th>
<th>MW</th>
<th>Chemical Formula</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lisinopril dehydrate</td>
<td>83915-83-7</td>
<td>--</td>
<td>441.52</td>
<td>C21H31O5N3·2H2O</td>
<td>100%</td>
</tr>
</tbody>
</table>

SECTION 4: FIRST AID MEASURES

**General advice:** Consult a physician. Show this safety data sheet to the doctor in attendance. Move out of dangerous area.

**If inhaled:** If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.

**In case of skin contact:** Take off contaminated clothing and shoes immediately. Wash off with soap and plenty of water. Consult a physician.

**In case of eye contact:** Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. Continue rinsing eyes during transport to hospital.

**If swallowed:** DO NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

SECTION 5: FIRE-FIGHTING MEASURES

**Conditions of flammability:** Not flammable or combustible.
SAFETY DATA SHEET
Cat# B2132-50, 250 Lisinopril dehydrate
SDS DATE: Jun 4, 2018
Suitable extinguishing media: Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special protective equipment for firefighters: Wear self-contained breathing apparatus for firefighting if necessary.
Hazardous combustion products: Hazardous combustion products formed under fire conditions — no data available.

SECTION 6: ACCIDENTAL RELEASE MEASURES

Personal precautions: Use personal protective equipment. Avoid breathing vapors, mist, gas, or dust. Avoid dust formation. Ensure adequate ventilation. Evacuate personnel to safe areas.
Environmental precautions: Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods for cleaning up: Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.

SECTION 7: HANDLING AND STORAGE

Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Provide appropriate exhaust ventilation at places where dust is formed.
Conditions for safe storage
Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: -20 °C

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

Contains no substances with occupational exposure limit values.
Personal protective equipment
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Hand protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove’s outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Eye protection
Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin and body protection
Complete suit protecting against chemicals. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.
Hygiene measures
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Lisinopril dehydrate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance:</td>
<td>White solid</td>
</tr>
<tr>
<td>pH:</td>
<td>No data available</td>
</tr>
<tr>
<td>Water Solubility:</td>
<td>No data available</td>
</tr>
<tr>
<td>Other Solubility:</td>
<td>H₂O (<del>10 mg/ml) or DMSO (</del> 5 mg/ml)</td>
</tr>
<tr>
<td>Specific Gravity (g/ml):</td>
<td>No data available</td>
</tr>
<tr>
<td>Boiling Point (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting Point (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash Point (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Ignition Temperature (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
</tbody>
</table>

SECTION 10: STABILITY AND REACTIVITY

<table>
<thead>
<tr>
<th>Property</th>
<th>Lisinopril dehydrate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical stability</td>
<td>Stable under recommended storage conditions</td>
</tr>
<tr>
<td>Conditions to avoid:</td>
<td>No data available</td>
</tr>
<tr>
<td>Materials to avoid:</td>
<td>Strong oxidizing agents, acids, acid anhydrides</td>
</tr>
<tr>
<td>Hazardous decomposition products:</td>
<td>No data available</td>
</tr>
</tbody>
</table>

SECTION 11: TOXICOLOGICAL INFORMATION

Lisinopril dehydrate:
Acute toxicity: no data available
SAFETY DATA SHEET
Cat# B2132-50, 250 Lisinopril dehydrate

Skin corrosion/irritation: no data available
Serious eye damage/eye irritation: no data available
Respiratory or skin sensitization: no data available
Germ cell mutagenicity: no data available
Carcinogenicity:
  IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.
  ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH.
  NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.
  OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.

Reproductive toxicity:
Reproductive toxicity - Rat - Oral
Effects on Newborn: Viability index (e.g., # alive at day 4 per # born alive). Effects on Newborn: Growth statistics (e.g., reduced weight gain).
Reproductive toxicity - Rat - Oral
Effects on Newborn: Behavioral.
No data available
Teratogenicity: no data available
Specific target organ toxicity – single exposure (GHS): no data available
Specific target organ toxicity – repeated exposure (GHS): no data available
Aspiration hazard: no data available
Signs and Symptoms of Exposure: To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
Synergistic effects: no data available
Additional information: RTECS: TW3589990

SECTION 12: ECOLOGICAL INFORMATION
Lisinopril dehydrate:
Persistence and degradability: no data available
Toxicity: no data available
Bioaccumulative potential: no data available
Mobility in soil: no data available
PBT and vPvB assessment: no data available
Other adverse effects: no data available

SECTION 13: DISPOSAL CONSIDERATIONS
Product: Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging: Dispose of as unused product.

SECTION 14: TRANSPORT INFORMATION
Lisinopril dehydrate:
DOT (US): Not dangerous goods.
IMDG: Not dangerous goods.
IATA: Not dangerous goods.

SECTION 15: REGULATORY INFORMATION
Lisinopril dehydrate:
SARA 302 Components: SARA 302: No chemical in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components: SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title II, Section 313.
SARA 311/312 Hazards: Chronic Health Hazard
Massachusetts Right To Know Components: No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components: Lisinopril dehydrate, CAS-No. 83915-83-7
New Jersey Right To Know Components: Lisinopril dehydrate, CAS-No. 83915-83-7
California Prop. 65 Components: This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

EU regulations

<table>
<thead>
<tr>
<th>Component</th>
<th>Risk Phrases</th>
<th>Safety Phrases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lisinopril dehydrate</td>
<td>R22, R34, R63</td>
<td>S22, S26, S36/37/39, S45</td>
</tr>
</tbody>
</table>

SECTION 16: OTHER INFORMATION